Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Treatment and Outcome of Early Onset Bipolar Disorder
- Conditions
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 40
- Registration Number
- NCT00048802
- Locations
- 🇺🇸
The Zucker Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, New York, United States
Switching Medication to Treat Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2002-09-05
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 219
- Registration Number
- NCT00044655
Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
- Conditions
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 530
- Registration Number
- NCT00036088
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT00035321
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. John, Canada
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 378
- Registration Number
- NCT00034801
Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder
- Conditions
- First Posted Date
- 2002-05-01
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 326
- Registration Number
- NCT00034580
Antipsychotic Response in Schizophrenia
- Conditions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018668
- Locations
- 🇺🇸
Department of Veterans Affairs, San Diego, California, United States
CATIE-Alzheimer's Disease Trial
- Conditions
- First Posted Date
- 2001-04-23
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 450
- Registration Number
- NCT00015548
- Locations
- 🇺🇸
VA Medical Center, Coatesville, Pennsylvania, United States
🇺🇸University of California, Irvine Medical Center, Irvine, California, United States
🇺🇸Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
CATIE- Schizophrenia Trial
- Conditions
- First Posted Date
- 2001-04-09
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 1600
- Registration Number
- NCT00014001
- Locations
- 🇺🇸
Staten Island University Hospital, Staten Island, New York, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Northwestern Medical School Department of Psychiatry, Chicago, Illinois, United States
To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2001-01-01
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 600
- Registration Number
- NCT00007774
- Locations
- 🇺🇸
VA Medical Center, Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania, United States
🇺🇸VA Medical Center, Bay Pines, Bay Pines, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.